Clinical Report: Network Meta-Analysis of Treatments for PCOS

Overview

This network meta-analysis evaluates the efficacy of glucagon-like peptide-1 receptor agonists, metformin, and inositol in enhancing metabolic and anthropometric outcomes in women with polycystic ovary syndrome (PCOS).

Background

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting up to 15% of women of reproductive age, associated with obesity and insulin resistance. Effective management is crucial as metabolic dysfunction can lead to long-term complications such as type 2 diabetes and cardiovascular disease. Current guidelines recommend lifestyle interventions as first-line therapy, but pharmacologic treatments are often necessary.

Data Highlights

Key Findings

• GLP-1 receptor agonists combined with metformin resulted in the greatest reductions in body weight and BMI.
• GLP-1 monotherapy significantly reduced waist circumference.
• No interventions showed significant effects on HOMA-IR.
• Results were marked by heterogeneity, but sensitivity analyses confirmed robustness for weight and BMI outcomes.
• Further long-term and head-to-head RCTs are needed to evaluate a broader range of outcomes.

Clinical Implications

Clinicians should remain aware of the limitations of these findings regarding broader reproductive and metabolic outcomes.

Conclusion

Further research is warranted to explore additional outcomes.

Related Resources & Content

1. Marchesan et al, The Journal of Clinical Endocrinology & Metabolism, 2026 -- Network Meta-Analysis of Treatments for PCOS
2. The Journal of Clinical Endocrinology & Metabolism — Exploring the Role of Topiramate and Metformin in Weight Management for PCOS: Insights and Future Research Directions
3. The Journal of Clinical Endocrinology & Metabolism — Combination of Topiramate and Metformin for Weight Management in Women Diagnosed with Polycystic Ovary Syndrome
4. Frontiers in Reproductive Health — Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications
5. JAMA Network Open — HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
6. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
7. Frontiers | Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis
8. Effects of GLP-1 Receptor Agonists vs Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis - PMC
9. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial | Reproductive Biology and Endocrinology | Springer Nature Link
10. Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map - PubMed
11. Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials